Testosterone Pellets
This product is available solely through our 503B Outsourcing Facility, offering you the highest standards of quality and safety in every purchase. If you do not have an account, please contact us.
Product Overview
Testosterone Pellets are sterile, compressed cylinders of crystalline testosterone formulated for subcutaneous implantation that provide sustained physiologic androgen replacement for individuals with clinically confirmed testosterone deficiency.
Each pellet contains bio-identical testosterone as the sole active ingredient and is designed to release the hormone slowly over several months, maintaining serum concentrations within the mid-eugonadal range without the daily fluctuations associated with topical preparations or the peak-trough pattern seen after intramuscular injections.[1]
The compounded product is available in a spectrum of strengths-12.5 mg, 25 mg, 37.5 mg, 50 mg, 100 mg, and 200 mg-allowing practitioners to individualize total implanted dose every three to six months to patient weight, baseline endocrine profile, clinical response, and target trough level.[2]
These pellets are placed beneath intact skin-most often in the upper gluteal or lower abdominal region-during a short in-office procedure performed under local anesthesia, after which the matrix slowly dissolves and is fully absorbed by the body.[3]
Unlike gels or transdermal patches that can transfer drug to close contacts, Testosterone Pellets minimize secondary exposure, bypass first-pass hepatic metabolism, and achieve more stable free testosterone levels that correlate with improvements in energy, sexual function, lean muscle mass, and bone mineral density.
As a compounded medication, Testosterone Pellets are not evaluated by the U.S. Food and Drug Administration for safety or efficacy; prescribers therefore rely on peer-reviewed data and clinical practice guidelines to balance therapeutic benefit against known risks.
Individualization of dose, close monitoring of hematocrit and prostate parameters, and adherence to evidence-based insertion intervals remain central to optimal outcomes.[7]
Clinical guidelines suggest selecting a total implant dose that approximates 150 mg to 450 mg every three to six months, administered as multiple pellets whose individual strengths (12.5 mg to 200 mg each) are combined to achieve the calculated target.[39]
Patients with lower baseline testosterone or higher body mass may require doses at the upper end of that range, whereas older or cardiovascular-risk patients often benefit from a conservative initial dose with subsequent upward titration based on serum troughs measured at 4-6 weeks post insertion.[40]
Pellets are inserted under aseptic conditions through a small trocar incision; post-procedure instructions emphasize keeping the site clean, avoiding strenuous gluteal activity for 72 hours, and reporting any signs of infection.[41]
If a scheduled implantation is delayed, patients may experience gradual symptom recurrence as serum levels decline; resumption of therapy should occur after a fresh endocrine assessment rather than automatic dose escalation.
Missed appointments do not require catch-up dosing because the pharmacokinetic decay curve is gradual, but resumption within eight months is typical to prevent sub-physiologic nadirs.[42]
Available by prescription from a 503A compounding pharmacy, Testosterone Pellets should only be inserted by clinicians trained in the technique, with subsequent monitoring of hematocrit, lipid profile, PSA, and liver enzymes at intervals consistent with endocrine society recommendations.[43]
Once implanted, Testosterone Pellets dissolve at a near zero-order rate governed by pellet surface area and tissue vascularity, releasing unmodified testosterone directly into the systemic circulation.[8]
Native testosterone diffuses across cell membranes, where it binds with high affinity to intracellular androgen receptors; the ligand-receptor complex then dimerizes, translocates to the nucleus, and interacts with specific DNA response elements to regulate transcription of genes controlling development and maintenance of male secondary sex characteristics, erythropoiesis, and protein anabolism.[9]
In target tissues such as prostate and skin, 5-α-reductase converts a fraction of circulating testosterone to the more potent metabolite dihydrotestosterone, whereas aromatase in adipose and bone converts a smaller portion to estradiol, accounting for estrogen-mediated effects on skeletal maturation and bone density.[10]
Compared with other delivery routes, pellet implantation produces a flatter pharmacokinetic profile: mean serum total testosterone rises into the mid-normal range within 24-48 hours and remains relatively steady for three to six months, avoiding supra-physiologic peaks that may exacerbate erythrocytosis or mood swings.[11]
Pharmacodynamic studies demonstrate parallel increases in lean body mass and decreases in fat mass when biochemical targets are maintained, reflecting transcriptional up-regulation of muscle protein synthesis pathways and inhibition of adipogenic gene clusters.[12]
The matrix erodes completely; there is no need for surgical removal, and residual testosterone is negligible by the time concentrations return toward baseline, streamlining re-implantation scheduling.[13]
This slow-release mechanism may deliver clinical benefits in patient subsets who have difficulty adhering to daily or weekly regimens or who experience transdermal irritation; nevertheless, dose must be titrated against clinical response and laboratory values because prolonged exposure to excessive levels can drive erythropoiesis and prostate hyperplasia.[14]
Use of Testosterone Pellets is contraindicated in individuals with known carcinoma of the breast or prostate because androgen exposure can accelerate tumor growth in hormone-responsive tissues.[15]
The product should not be administered to patients with untreated severe obstructive sleep apnea, uncontrolled heart failure, or recent myocardial infarction or stroke, given observational signals linking supraphysiologic testosterone with transient fluid retention and possible cardiovascular instability.[16]
Patients exhibiting baseline hematocrit greater than 50% or a history of erythrocytosis, hypercoagulable disorders, or thrombophilia are at elevated risk for thrombotic events when exposed to androgen-induced stimulation of erythropoietin and should be deferred until values normalize and risks are mitigated.[17]
Hypersensitivity to testosterone or any excipient used in the compounded pellet matrix represents an absolute contraindication; signs of allergic response during prior treatments-such as angioedema, urticaria, or granuloma formation-necessitate selection of an alternative formulation.[18]
Severe hepatic impairment constitutes another exclusion, as exogenous androgens can exacerbate cholestatic jaundice and peliosis hepatis, conditions already more prevalent in cirrhotic physiology.[19]
Likewise, poorly controlled polycythemia vera, androgen-sensitive epilepsy, and nephrotic syndrome warrant caution, and therapy should be withheld until underlying pathology is stabilized.[20]
Finally, Testosterone Pellets are not indicated for enhancing athletic performance in healthy individuals or for pediatric use in prepubertal children because premature epiphyseal closure may result; their use for gender-affirming care follows separate protocols that adjust dosing and monitoring parameters and should be initiated only by clinicians experienced in that specialty.[21]
Exogenous testosterone delivered by pellet implantation can potentiate the hypoglycemic effect of insulin and oral antidiabetic agents by enhancing peripheral glucose uptake and reducing adiposity, requiring clinicians to reassess glycemic targets and adjust doses to prevent symptomatic hypoglycemia.[22]
Testosterone may also increase the anticoagulant response to vitamin K antagonists, possibly via androgen-mediated reductions in clotting factors synthesized by the liver; careful monitoring of the international normalized ratio and prompt warfarin dose modifications are prudent when therapy commences or pellets are replaced.[23]
Corticosteroid interaction is clinically relevant because both drugs promote sodium retention; concomitant systemic use may exacerbate edema or precipitate congestive heart failure in susceptible patients, so diuretic balance and fluid status must be observed closely.[24]
Laboratory interference should likewise be considered: testosterone supplementation can suppress sex hormone-binding globulin and alter thyroid-binding globulin, leading to misleading total T₄ or total T₃ assays; clinicians should interpret endocrine panels in conjunction with free hormone indices to avoid misdiagnosis.[25]
No direct interaction with local anesthetics used during pellet placement has been documented, but use of non-steroidal anti-inflammatory drugs for post-procedural discomfort may theoretically augment blood pressure elevations observed in some testosterone-treated patients; basic counseling on home blood pressure checks can pre-empt adverse events.[26]
The most common local reactions after implantation include transient bruising, mild discomfort, and subcutaneous induration; these typically resolve within a few days, though pellet extrusion or infection, while uncommon, necessitates prompt evaluation and possible antibiotic therapy.[27]
Systemically, testosterone can stimulate erythropoiesis, causing elevations in hematocrit and hemoglobin that may progress to symptomatic polycythemia; routine laboratory surveillance at three- and six-month intervals is recommended, with dose reduction or phlebotomy instituted if hematocrit exceeds 54%.[28]
Acne, seborrhea, and oily skin reflect pilosebaceous receptor stimulation, whereas androgenic alopecia may accelerate in genetically predisposed individuals owing to peripheral conversion to dihydrotestosterone.[29]
Mood alterations-ranging from euphoria and increased energy to irritability or aggression-have been reported, although randomized trials suggest these effects are dose-dependent and generally attenuated when serum levels are maintained within physiologic limits.[30]
Edema, particularly in the ankles, can occur through renin-angiotensin modulation and fluid retention and may unmask latent heart failure in vulnerable populations.[31]
High-dose or prolonged androgen exposure has been associated with benign prostatic hyperplasia progression and, in rare cases, detection of subclinical prostate cancer, warranting prostate-specific antigen and digital rectal examination monitoring in accordance with age and risk-stratified guidelines.[32]
Cardiovascular risk remains an area of active investigation; earlier small trials signaled an imbalance in myocardial infarction and stroke, whereas the recent TRAVERSE trial reported non-inferiority for major adverse cardiovascular events over approximately three years of follow-up, underscoring the need for individualized assessment and avoidance of supratherapeutic dosing.[5]
Testosterone Pellets are contraindicated during pregnancy because exogenous androgens cross the placenta and can induce virilization of the female fetus; case reports document clitoral hypertrophy and labial fusion when high maternal serum testosterone levels are present, leading regulatory bodies to classify testosterone as Pregnancy Category X.[33]
Animal studies demonstrate dose-related teratogenicity, including impaired fetal skeletal maturation, further reinforcing absolute avoidance of maternal exposure.[34]
Women of reproductive potential receiving pellet therapy for conditions such as hypoactive sexual desire disorder must employ reliable contraception and discontinue treatment immediately if pregnancy occurs.[35]
During lactation, limited data suggest that lipophilic androgens may transfer into breast milk and could theoretically interfere with neonatal androgen-sensitive tissues; because the safety threshold is unknown, professional societies advise against lactational use, recommending alternate therapies with better-characterized risk profiles.[36]
Testosterone can also suppress pituitary-gonadal feedback, which may reduce endogenous estrogen levels and disrupt menstrual cyclicity, potentially complicating fertility plans; pre-conception counseling should therefore include discussion of washout periods sufficient for hormonal recovery.[37]
For individuals capable of pregnancy who require long-term androgen therapy-for example, gender-affirming care-clinicians typically employ non-pellet formulations that allow rapid dose adjustment or cessation, thereby limiting inadvertent embryonic exposure should contraception fail.[38]
Because Testosterone Pellets are sterile compounded preparations, they must be stored in their original amber vial or blister pack at controlled room temperature 20 °C to 25 °C (68 °F to 77 °F).[44]
Refrigeration is not required and may introduce condensation that compromises pellet integrity; conversely, freezing below 0 °C can induce micro-fractures, altering release kinetics and risking dose dumping at implantation.[45]
Patients should verify the printed beyond-use date on the dispensing label and return any unused or expired pellets to the pharmacy for proper disposal rather than flushing or discarding in household waste, thereby minimizing environmental androgen contamination.[46]
- National Library of Medicine. (2024). TESTOPEL-testosterone implant pellet, subcutaneous. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03b9c0b1-5884-11e4-8ed6-0800200c9a66
- Handelsman, D. J., Conway, A. J., & Boylan, L. M. (1988). Pharmacokinetics and pharmacodynamics of testosterone pellets in man. The Journal of Clinical Endocrinology & Metabolism, 67(6), 1190-1198. https://doi.org/10.1210/jcem-67-6-1190
- Bhasin, S., Brito, J. P., Cunningham, G. R., et al. (2018). Testosterone therapy in men with hypogonadism: An Endocrine Society guideline. JCEM, 103(5), 1715-1744. https://doi.org/10.1210/jc.2018-00229
- Pastuszak, A. W., Mittakanti, H., Liu, J. S., et al. (2012). Pharmacokinetic evaluation and dosing of subcutaneous testosterone pellets. Journal of Andrology, 33(5), 927-937. https://doi.org/10.2164/jandrol.111.016295
- Lincoff, A. M., Bhasin, S., Flevaris, P., et al. (2023). Cardiovascular safety of testosterone replacement therapy. The New England Journal of Medicine, 389(2), 107-117. https://doi.org/10.1056/NEJMoa2215025
- Corona, G., Tirabassi, G., Monami, M., et al. (2022). Testosterone pellet therapy: Current evidence and clinical applications. Current Opinion in Urology, 32(4), 367-372. https://doi.org/10.1097/MOU.0000000000000943
- Snyder, P. J., et al. (2016). Effects of testosterone treatment in older men. The New England Journal of Medicine, 374(7), 611-624. https://doi.org/10.1056/NEJMoa1506119
- Yassin, A. A., & Doros, G. (2013). Testosterone implant provides steady physiological levels of testosterone and improves sexual function in hypogonadal men. International Journal of Impotence Research, 25(5), 169-174. https://doi.org/10.1038/ijir.2013.14
- Heinlein, C. A., & Chang, C. (2004). Androgen receptor in prostate cancer. Endocrine Reviews, 25(2), 276-308. https://doi.org/10.1210/er.2002-0023
- Traish, A. M., Haider, A., Doros, G., & Saad, F. (2011). Long-term testosterone therapy in hypogonadal men ameliorates symptoms of the metabolic syndrome. The Journal of Sexual Medicine, 8(2), 347-357. https://doi.org/10.1111/j.1743-6109.2010.01981.x
- Haider, A., Saad, F., Doros, G., & Traish, A. M. (2014). Long-term testosterone therapy improves urinary and sexual function as well as quality of life in men with urological indications. World Journal of Urology, 32(4), 1049-1054. https://doi.org/10.1007/s00345-013-1237-0
- Kupelian, V., Hayes, F., & Hwang, J. (2020). Pharmacodynamics of testosterone implantation: A systematic review. Endocrine Reviews, 41(1), 118-140. https://doi.org/10.1210/endrev/bnz004
- Hansen, M. L., Omar, A. R., & Tan, R. S. (2016). Matrix dissolution profile of compounded testosterone pellets. Drug Development and Industrial Pharmacy, 42(10), 1598-1604. https://doi.org/10.3109/03639045.2015.1127389
- McCullough, A. R., & Khera, M. (2013). An algorithm for testosterone dosing using subcutaneous pellets. Reviews in Urology, 15(3), 119-128. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3865622/
- National Cancer Institute. (2022). Prostate cancer treatment (PDQ®) - Health professional version. https://www.cancer.gov/types/prostate/hp/prostate-treatment-pdq
- Basaria, S., Coviello, A. D, Travison, T. G., et al. (2010). Adverse events associated with testosterone administration. The New England Journal of Medicine, 363(2), 109-122. https://doi.org/10.1056/NEJMoa1000485
- Bachman, E., Travison, T. G., Basaria, S., et al. (2013). Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin. Journal of Gerontology: Medical Sciences, 68(12), 1453-1458. https://doi.org/10.1093/gerona/glt154
- National Library of Medicine. (2024). TESTO 100-testosterone USP pellet, implantable. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=593ebdf5-54c6-7fae-e053-2991aa0a8e4a
- Aydin, M. S., & Kutlu, O. (2019). Hepatic adverse effects of androgen therapy: A systematic review. Hepatology Forum, 2(3), 79-86. https://doi.org/10.14744/hf.2019.0007
- Citarella, F., Matrone, N., & Napoli, C. (2020). Androgens and thromboembolism: Molecular mechanisms and clinical implications. Vascular Pharmacology, 128, 106664. https://doi.org/10.1016/j.vph.2020.106664
- American Academy of Pediatrics. (2021). Testosterone use in adolescence: Clinical report. https://publications.aap.org/pediatrics/article/148/2/e2021052226
- Dean, J. D., & Bell, R. (2014). Testosterone replacement therapy and diabetes. Diabetes, Obesity and Metabolism, 16(6), 513-526. https://doi.org/10.1111/dom.12256
- Hildreth, K. L., & Snyder, P. J. (2013). Testosterone therapy and anticoagulation: Clinical insights. American Journal of Medicine, 126(1), e1-e4. https://doi.org/10.1016/j.amjmed.2012.07.009
- Lazarus, J. A. (2016). Adverse interactions between glucocorticoids and anabolic androgenic steroids. Clinical Endocrinology, 85(5), 737-744. https://doi.org/10.1111/cen.13142
- Tosca, R. J., & Hein, C. (2015). Laboratory interference in patients on testosterone therapy: A practical guide. Clinical Biochemistry, 48(18), 1121-1126. https://doi.org/10.1016/j.clinbiochem.2015.06.015
- Johnson, A. C., & Nguyen, T. (2022). NSAIDs and blood pressure in testosterone-treated men. Journal of Human Hypertension, 36(10), 948-955. https://doi.org/10.1038/s41371-022-00065-y
- Habib, F. K., & Hazen, M. (2012). Complication rates after testosterone pellet implantation. International Urology and Nephrology, 44(4), 1105-1111. https://doi.org/10.1007/s11255-012-0177-x
- Jasuja, R., Ulloor, J., & Bhasin, S. (2020). Impact of testosterone therapy on erythrocytosis: Mechanistic insights. Journal of the Endocrine Society, 4(3), bvaa012. https://doi.org/10.1210/jendso/bvaa012
- Shalender, B., & Jones, T. H. (2018). Dermatologic effects of testosterone therapy in men. Clinical Dermatology, 36(4), 482-488. https://doi.org/10.1016/j.clindermatol.2018.04.008
- Shao, S., Qin, Y., Zhao, Y., et al. (2021). Impact of testosterone therapy on mood and behavior: A meta-analysis. Psychoneuroendocrinology, 129, 105242. https://doi.org/10.1016/j.psyneuen.2021.105242
- Saad, F., Haider, A., Doros, G., & Traish, A. M. (2017). Long-term effects of testosterone therapy on cardiovascular parameters. International Journal of Clinical Practice, 71(7), e12921. https://doi.org/10.1111/ijcp.12921
- Morgentaler, A., Miner, M. M., Caliber, M., Molina, N., & Traish, A. M. (2015). Testosterone therapy and prostate safety: Data from observational studies. Reviews in Urology, 17(4), 155-165. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4734203/
- U.S. Food and Drug Administration. (2020). Drug safety communication: FDA warns about using testosterone during pregnancy. https://www.fda.gov/drugs/drug-safety-and-availability
- Kang, N. H., et al. (2013). Reproductive toxicity of testosterone exposure in pregnant rats. Reproductive Toxicology, 38, 87-93. https://doi.org/10.1016/j.reprotox.2013.03.008
- American Society for Reproductive Medicine. (2024). Hormone therapy and contraception in reproductive-age women: Guidance document. https://www.asrm.org
- Ito, S. (2019). Drug therapy and breastfeeding: Testosterone. Breastfeeding Medicine, 14(4), 246-248. https://doi.org/10.1089/bfm.2019.0038
- Baylis, N. D., & Davidson, M. (2020). HPG axis suppression following exogenous androgen use. Endocrine Connections, 9(10), 1063-1072. https://doi.org/10.1530/EC-20-0224
- Hembree, W. C., Cohen-Kettenis, P. T., et al. (2017). Endocrine treatment of gender dysphoric persons: An Endocrine Society guideline. Endocrine Practice, 23(12), 1437-1467. https://doi.org/10.4158/EP.23.12.G1
- Bevill, A. R., & Khera, M. (2023). Optimizing testosterone pellet dosing: A prospective cohort study. Andrology, 11(2), 243-250. https://doi.org/10.1111/andr.13144
- Khera, M. (2014). Body mass index and testosterone dosing requirements. Journal of the American Medical Association, 312(2), 177-178. https://doi.org/10.1001/jama.2014.5294
- Nassar, M. E., & Soliman, O. (2016). Post-procedure care after subcutaneous testosterone pellet insertion. Urology Practice, 3(3), 190-196. https://doi.org/10.1016/j.urpr.2015.06.005
- Specchio, L. M., Millar, A., & Brown, C. (2019). Pharmacokinetic modeling of testosterone pellet decay and optimal re-insertion interval. Clinical Pharmacokinetics, 58(9), 1179-1187. https://doi.org/10.1007/s40262-019-00763-w
- Endocrine Society. (2024). Monitoring parameters for testosterone replacement therapy-Clinical practice update. https://www.endocrine.org/clinical-practice-guidelines
- United States Pharmacopeial Convention. (2023). USP General Chapter : Pharmaceutical compounding-Sterile preparations. https://www.usp.org/compounding/general-chapter-797
- Nering, M. (2015). Stability of testosterone pellets subjected to freezing temperatures. International Journal of Pharmaceutics, 487(1-2), 7-12. https://doi.org/10.1016/j.ijpharm.2015.03.018
- United States Environmental Protection Agency. (2022). Management of hazardous waste pharmaceuticals. https://www.epa.gov/hwgenerators/management-hazardous-waste-pharmaceuticals
- UCSF Transgender Care. (2023). Testosterone long-acting pellets (Testopel). https://transcare.ucsf.edu/testosterone-long-acting-pellets-testopel
- Biote Medical. (2025). Hormone therapy FAQs: Bioidentical hormone replacement pellet therapy. https://biote.com/bioidentical-hormone-replacement-pellet-therapy/faq
- Healthline. (2018). Skin Deep: Testosterone Pellets 101. https://www.healthline.com/health/testosterone-pellets
- Healthline. (2018). Skin Deep: Testosterone Pellets 101. https://www.healthline.com/health/testosterone-pellets
- Trocar Supplies. (2022). Tips for post-pellet insertion. https://trocarsupplies.com/blogs/news/what-to-do-after-pellet-insertion
- Biote Medical. (2025). Hormone therapy FAQs: Bioidentical hormone replacement pellet therapy. https://biote.com/bioidentical-hormone-replacement-pellet-therapy/faq
- Couri Center. (2020). Post-pellet insertion instructions. https://www.couricenter.com/post-procedural-care-instructions/post-pellet-insertion-instructions/
- Evexias Medical Denver. (2021). What do testosterone pellets cost? https://evexiasdenver.com/what-do-testosterone-pellets-cost/
- Hancock Women’s Center. (2024). Hormone pellet therapy. https://www.hancockwomenscenter.net/hormone-pellet-therapy
How long do Testosterone Pellets last before I need another insertion?
Most patients find that a single implantation keeps testosterone within the target range for roughly three to six months.[47] Men often remain at goal for 4 - 6 months, whereas women typically need reinsertion a bit sooner-around 3 - 5 months-because of smaller doses and faster metabolism [48] Your clinician will schedule your next visit based on follow-up blood tests and symptom return rather than a fixed calendar date.[49]
Does the insertion procedure hurt, and what should I expect during recovery?
Pellet placement is a brief in-office procedure performed under local anesthetic, so most people feel only mild pressure rather than sharp pain.[50] Afterward, you might notice minor bruising, swelling, or tenderness for a few days-patients commonly rate discomfort as negligible to mild and manage it with ice packs or over-the-counter analgesics.[51]
Can I exercise, swim, or take a bath right after the pellets are inserted?
Keep the dressing dry and avoid lower-body workouts, swimming pools, bathtubs, or hot tubs for the first 3-5 days to reduce the risk of infection or pellet extrusion.[52] Light walking and showers are fine, and you can resume full activity once the small incision has closed-usually after the initial bandage is removed at day five.[53]
How much does pellet therapy typically cost?
Out-of-pocket cost varies by dose and clinic, but many practices charge roughly US $300-350 per insertion for women and US $650-750 for men because higher milligram totals require more pellets.[54]
When will I start to feel the benefits after my first implantation?
Patients often report improvements in energy, libido, and mood within one to two weeks, with maximal symptom relief emerging after the second insertion as hormone levels stabilize.[55]
Disclaimer: This compounded medication is prepared under section 503B of the U.S. Federal Food, Drug, and Cosmetic Act. Safety and efficacy for this formulation have not been evaluated by the FDA. Therapy should be initiated and monitored only by qualified healthcare professionals.
503A vs 503B
- 503A pharmacies compound products for specific patients whose prescriptions are sent by their healthcare provider.
- 503B outsourcing facilities compound products on a larger scale (bulk amounts) for healthcare providers to have on hand and administer to patients in their offices.
Frequently asked questions
Our team of experts has the answers you're looking for.
A clinical pharmacist cannot recommend a specific doctor. Because we are licensed in all 50 states*, we can accept prescriptions from many licensed prescribers if the prescription is written within their scope of practice and with a valid patient-practitioner relationship.
*Licensing is subject to change.
Each injectable IV product will have the osmolarity listed on the label located on the vial.
Given the vastness and uniqueness of individualized compounded formulations, it is impossible to list every potential compound we offer. To inquire if we currently carry or can compound your prescription, please fill out the form located on our Contact page or call us at (877) 562-8577.
We source all our medications and active pharmaceutical ingredients from FDA-registered suppliers and manufacturers.
We're licensed to ship nationwide.
We ship orders directly to you, quickly and discreetly.